Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRoquefort Thera Regulatory News (ROQ)

  • There is currently no data for ROQ

Board Changes

20 Oct 2021 07:00

RNS Number : 5782P
Roquefort Investments PLC
20 October 2021
 

20 October 2021

 

 

Roquefort Investments plc

("Roquefort Investments" or the "Company")

 

Board Changes

 

Roquefort Investments (LSE:ROQ), the investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector, announces the appointment of Mr Mark Freeman as a non-executive director and the resignation of Mr Glenn Whiddon as non-executive director with effect from today.

 

Mr Freeman (aged 46) is a Chartered Accountant and has more than 25 years' experience in corporate finance and the public markets, with a focus on project development. Mr Freeman is a graduate of the University of Western Australia with a Bachelor of Commerce with a double major in Banking & Finance and Accounting as well as holding a Graduate Diploma in Applied Finance with a major in Investment Analysis from the Securities Institute of Australia. He has experience in strategic planning, business development, acquisitions and mergers, project commercialisation, project development and general management. Mr Freeman is currently a director of Pursuit Minerals Ltd (ASX:PUR), Calima Energy Ltd (ASX:CE1) and Grand Gulf Energy Ltd (ASX:GGE).

 

In addition, Mr Freeman is currently a director of Lyramid Limited ("Lyramid"). It is intended that Mr Freeman will retain his position as one of the two Australian resident directors required to be appointed to the Board of Lyramid after the proposed acquisition of Lyramid has completed.

 

Stephen West, Executive Chairman, commented:

"As we work towards completion of the Lyramid transaction, it is important to have a financially oritentated Australian resident director with public markets experience to assist the Company going forward. We are therefore delighted that Mark Freeman has agreed to join the Company as a non-executive director given his proven track record and experience in this regard. I would like to thank Glenn Whiddon for working with us from the formation of Roquefort Investments up to this transformational stage for the Company.

 

The Board is focused on completing the Lyramid transaction and the RTO process and we look forward to providing a further update on this shortly."

 

Enquiries:

 

Roquefort Investments plc

Stephen West (Chairman)

+44 (0)20 3290 9339

Optiva Securities Limited (Joint Broker)

 

Christian Dennis

+44 (0) 20 3411 1881

 

For further information, please visit www.roquefortinvest.com and @roquefortinvest on Twitter.

 

LEI: ‎254900P4SISIWOR9RH34

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAFFEFIUEFSEIS
Date   Source Headline
26th Mar 20261:00 pmRNS-RInvestor Presentation
26th Mar 202612:08 pmRNSResult of General Meeting
25th Mar 20267:00 amRNSLyramid SPA & MK Cell License Update
2nd Mar 20268:00 amRNSSchedule One - Roquefort Therapeutics PLC
2nd Mar 20267:00 amRNSProposed Acquisition and Fundraise of £8.5 million
25th Feb 20267:00 amRNSTransaction Update & Notice of Intention to Delist
15th Jan 20267:00 amRNS-RResearch Note Published
12th Dec 20257:00 amRNSClinical Trial & License Agreement Update
9th Dec 20257:00 amRNSConversion of CLNs
1st Dec 202510:35 amRNSEx-Entitlement Date - Unlisted RNV Shares
1st Dec 20257:00 amRNSDetermination of Record Date and Entitlement
25th Nov 20257:00 amRNSHolding(s) in Company
24th Nov 20257:00 amRNSDirector/PDMR Shareholding
18th Nov 20257:00 amRNSExecuted License Agreement & Transaction Update
3rd Nov 20257:00 amRNSMK Cell Out-License & Lyramid SPA Update
16th Oct 20257:00 amRNSFundraise & Transaction Update
30th Sep 20257:00 amRNSInterim Results to 30 June 2025
24th Sep 20257:00 amRNS-RInvestor Presentation via Engage Investor
8th Sep 20257:00 amRNSProposed Acquisition of Clinical Stage Company
28th Aug 20257:00 amRNSLyramid SPA 2nd Extension & Carve Out
7th Jul 20257:00 amRNSDirector/PDMR Shareholding
30th Jun 20257:00 amRNSDirector/PDMR Shareholding
27th Jun 20257:00 amRNSLyramid SPA Extension
26th Jun 20251:00 pmRNSResults of AGM
13th Jun 20254:00 pmRNSIssue of Equity
2nd Jun 20257:00 amRNSNotice of Annual General Meeting
23rd May 20257:00 amRNSExtension of Convertible Loan Notes
13th May 20257:00 amRNSCorporate Update
30th Apr 20257:00 amRNSAnnual Report & Financial Statements - 31 Dec 2024
14th Mar 20257:00 amRNSPrivate Placing and Conversion of CLNs
10th Mar 20257:30 amRNSBoard Changes
10th Mar 20257:00 amRNSProposed Sale of Oncogeni Ltd
4th Mar 20257:00 amRNSUpdate on Sale of Lyramid
4th Feb 202510:58 amRNSDirector/PDMR Shareholding
3rd Feb 20257:00 amRNSShare Purchase Agreement Signed - Sale of Lyramid
2nd Jan 20257:00 amRNSProposed Sale of Midkine Portfolio
4th Dec 20244:00 pmRNSDirector Share Distribution
7th Nov 20247:00 amRNSConversion of Convertible Loan Notes
27th Sep 20247:00 amRNSInterim Results to 30 June 2024
23rd Sep 20247:00 amRNSGrant of Japan MK Cell Patent
19th Sep 20247:00 amRNSSTAT-6 siRNA Demonstrates Efficacy in Immunology
2nd Sep 20247:00 amRNSGrant of MK Cell Patent & Licencing Update
27th Jun 202412:46 pmRNSResults of AGM
20th Jun 20247:00 amRNSAppointment of Broker
4th Jun 20247:00 amRNSNotice of Annual General Meeting
23rd May 20247:05 amRNSIssue of Convertible Loan Notes & Board Changes
23rd May 20247:00 amRNSMidkine Antibody Licencing Deal
26th Apr 20247:00 amRNSAnnual Report & Financial Statements - 31 Dec 2023
5th Apr 20247:00 amRNSResponse to Share Price Movement
11th Mar 20247:00 amRNSPositive Results: Midkine mRNA and STAT-6 siRNA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.